| Literature DB >> 30853933 |
Carina Kelbsch1, Torsten Strasser1, Yanjun Chen2, Beatrix Feigl3,4,5, Paul D Gamlin6, Randy Kardon7, Tobias Peters1, Kathryn A Roecklein8, Stuart R Steinhauer9,10, Elemer Szabadi11, Andrew J Zele3,12, Helmut Wilhelm1, Barbara J Wilhelm1.
Abstract
The number of research groups studying the pupil is increasing, as is the number of publications. Consequently, new standards in pupillography are needed to formalize the methodology including recording conditions, stimulus characteristics, as well as suitable parameters of evaluation. Since the description of intrinsically photosensitive retinal ganglion cells (ipRGCs) there has been an increased interest and broader application of pupillography in ophthalmology as well as other fields including psychology and chronobiology. Color pupillography plays an important role not only in research but also in clinical observational and therapy studies like gene therapy of hereditary retinal degenerations and psychopathology. Stimuli can vary in size, brightness, duration, and wavelength. Stimulus paradigms determine whether rhodopsin-driven rod responses, opsin-driven cone responses, or melanopsin-driven ipRGC responses are primarily elicited. Background illumination, adaptation state, and instruction for the participants will furthermore influence the results. This standard recommends a minimum set of variables to be used for pupillography and specified in the publication methodologies. Initiated at the 32nd International Pupil Colloquium 2017 in Morges, Switzerland, the aim of this manuscript is to outline standards in pupillography based on current knowledge and experience of pupil experts in order to achieve greater comparability of pupillographic studies. Such standards will particularly facilitate the proper application of pupillography by researchers new to the field. First we describe general standards, followed by specific suggestions concerning the demands of different targets of pupil research: the afferent and efferent reflex arc, pharmacology, psychology, sleepiness-related research and animal studies.Entities:
Keywords: analysis; application of pupillography; clinical standards; parameters of evaluation; pupillography; pupillometry; stimulus characteristics
Year: 2019 PMID: 30853933 PMCID: PMC6395400 DOI: 10.3389/fneur.2019.00129
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Overview of the MINI recommendations of the CARMEN consortium (62) adapted for pupillography.
Figure 4Targets of drugs in the neuronal network controlling the pupil. The pupil is an aperture in a diaphragm, the iris. The size of the pupil reflects the interaction between the circular sphincter muscle and the radial dilator muscle. The sphincter receives a parasympathetic and the dilator a sympathetic output. Both autonomic outputs consist of serially linked preganglionic and postganglionic neurones that are under the influence of premotor autonomic neurones. The premotor neurones channel the influence of other brain structures (e.g., cortex) and light to the preganglionic neurones. Premotor neurones: SCN: suprachiasmatic nucleus (hypothalamus); PVN: paraventricular nucleus (hypothalamus); LC: locus coeruleus (brainstem: pons); OPN: olivary pretectal nucleus (pretectum). Preganglionic neurones: IML: intermediate lateral column (spinal cord); EWN: Edinger-Westphal nucleus (brainstem: midbrain). Postganglionic neurones: SCG: superior cervical ganglion; GC: ciliary ganglion. Arrows are neuronal connections, red arrows are excitatory connections with identified neurotransmitters (Glu, glutamate; NA, noradrenaline; Ach, acetylcholine). Drugs can be applied topically to the surface of the cornea to affect the iris and the noradrenergic and cholinergic neuro-effector junctions, or systemically when they can affect any part of the central neuronal network. It should be noted that topically applied drugs may get into the systemic circulation leading to systemic effects, and systemically applied drugs may also affect the iris directly.
Effect of drug treatment on the pupil.
| Pilocarpine | cholinergic | miosis |
| Carbachol | cholinergic | miosis |
| Aceclidine | cholinergic | miosis |
| Atropine | anticholinergic | mydriasis |
| Scopolamine | anticholinergic | mydriasis |
| Tropicamide | anticholinergic | mydriasis |
| Phenylephrine | α1-adrenoceptor agonist | mydriasis |
| Methoxamine | α1-adrenoceptor agonist | mydriasis |
| Apraclonidine | α1-adrenoceptor agonist | mydriasis |
| Dapiprazole | α1-adrenoceptor antagonist | miosis |
| Brimonidine | α2-adrenoceptor agonist | miosis |
| Cocaine | noradrenaline uptake inhibitor | mydriasis |
| Antihistamines | H1 histamine receptor antagonists | miosis |
| Prazosin | α1-adrenoceptor antagonist | miosis |
| Clonidine | α2-adrenoceptor agonist | miosis |
| Disopyramide | anticholinergic | mydriasis |
| Anticholinergics | blockade of muscarinic receptors | mydriasis |
| Dopaminergics | stimulation of D2 dopamine receptors | mydriasis |
| Tricyclic | mainly noradrenaline uptake blockade | mydriasis |
| Reboxetine | noradrenaline uptake blockade | mydriasis |
| Venlafaxine | noradrenaline/serotonin uptake blockade | mydriasis |
| SSRIs | serotonin uptake blockade | no effect |
| Phenothiazines | α1-adrenoceptor antagonist, sedation | miosis |
| Haloperidol | α1-adrenoceptor antagonist | miosis |
| Benzodiazepines | GABA receptor agonist → sedation | no effect |
| Amphetamine | noradrenaline releaser | mydriasis |
| Modafinil | dopamine uptake blocker | mydriasis |
| Opiates | stimulation of inhibitory μ receptors | miosis |
| Scopolamine | anticholinergic | mydriasis |
| anticholinergic | mydriasis | |
glaucoma treatment.
myopia treatment.
in Horner's syndrome (supersensitive α.
drug reduces noradrenaline release (glaucoma treatment).
first generation antihistamines (e.g., diphenhydramine, cyclizine) penetrate into the brain where they block H1 histamine receptors, leading to sedation.
drug blocks α.
drug stimulates inhibitory α.
include orphenadrine, procyclidine, trihexyphenidyl.
D2 dopamine receptor agonists (e.g., pramipexole) stimulate inhibitory D2 receptors on wake-promoting central dopaminergic neurones, leading to sedation. This is expected to cause miosis, however, paradoxically, pramipexole causes mydriasis [see (.
Tricyclic antidepressants block the uptake of noradrenaline, potentiating noradrenergic neurotransmission, and this would lead to mydriasis. However, they have some other effects: blockade of muscarinic cholinoceptors would lead to mydriasis and sedation, and blockade of α.
Selective serotonin reuptake inhibitors (SSRIs) block serotonin receptors in a complex network of serotonergic neurones associated with different excitatory/inhibitory receptors. The overall effect is little or no change in pupil diameter.
These drugs (e.g., chlorpromazine, trifluoperazine) also have anticholinergic effects that would lead to mydriasis. However, α.
Paradoxically, although the benzodiazepine diazepam is highly sedative, it has no effect on pupil diameter [see (.
Modafinil blocks dopamine uptake at exciatatory synapses on central noradrenergic neurones: this leads to increase in arousal and sympathetic activity.
Stimulation of inhibitory μ receptors on central noradrenergic neurones leads to sedation and sympatholysis.
These drugs (oxybutynin, festerodine) inhibit voiding of the urinary bladder by blocking cholinoceptors in the detrusor muscle.
Figure 1The pupillary pathway. The afferent pupillary pathway comprises the retinal photoreceptors, the bipolar cells and the retinal ganglion cells whose axons form the optic nerve. Temporal fibers run ipsilaterally while the nasal fibers cross to the contralateral side in the optic chiasm. Afterwards, they form the optic tract and synapse at the olivary pretectal nucleus therefrom connecting to both Edinger Westphal nuclei (blue continuous line). The efferent pathway from the Edinger Westphal nucleus to the pupillary sphincter via the ciliary ganglion is depicted in dashed lines.
Figure 2Post-Illumination Pupil Response (PIPR) metrics. Consensual pupillary response to 1 s pulses (horizontal blue line at time 0; 465 nm blue, 637 nm red-the gray line represents the pre- and post-stimulus periods in the dark) measured in Maxwellian view (35.6° diameter stimulus; 15.1 log quanta.cm−2.s−1). Details of the pupil light response (PLR) and Post-Illumination Pupil Response (PIPR) metrics are described in the figure. Data are for a representative healthy observer (traces are the average of 3 repeats). Traces courtesy of Prakash Adhikari, Beatrix Feigl and Andrew J. Zele.
Figure 3Pupil diameter (mm) measured in darkness after switching off a light stimulus over a time period of 20 s. The right eye (R) shows the typical quick redilation behavior of a healthy pupil while the left eye (L) reveals a dilation lag, typical for Horner syndrome. Data are taken from a patient with Horner syndrome in the left eye collected during standard care.